ライフサイエンスコーパス: bronchiolitis obliterans

1 the development of interstitial fibrosis and bronchiolitis obliterans.

2 is include idiopathic pneumonia syndrome and bronchiolitis obliterans.

3 lung transplant might be an option to treat bronchiolitis obliterans.

4 istologically, the condition is often called bronchiolitis obliterans.

5 ssary to overcome the challenge presented by bronchiolitis obliterans.

6 ure is small airway obstruction arising from bronchiolitis obliterans.

7 hurdle to overcome in long-term survival is bronchiolitis obliterans.

8 roduction plant were reported to have severe bronchiolitis obliterans.

9 ssue fibrosis manifesting as scleroderma and bronchiolitis obliterans.

10 incidence of acute rejection; none developed bronchiolitis obliterans.

11 and pulmonary dysfunction characteristic of bronchiolitis obliterans.

12 The most common causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61,

13 One-year survival was 77% for patients with bronchiolitis obliterans, 37% for patients with IPS, and

14 e bronchiolitis (obliterative bronchiolitis, bronchiolitis obliterans), acute bronchiolitis, diffuse

15 , is of limited accuracy in diagnosing early bronchiolitis obliterans after lung transplantation.

16 V is also associated with the development of bronchiolitis obliterans after transplantation, we deter

17 , IL-6 may play a role in the development of bronchiolitis obliterans after transplantation.

18 Asthma as well as bronchiolitis obliterans and chronic bronchitis are chro

19 d prognostic features distinguishing it from bronchiolitis obliterans and idiopathic pulmonary fibros

20 nchiolitis, cystic fibrosis, post-transplant bronchiolitis obliterans and more recently chronic obstr

21 use of the associations between diacetyl and bronchiolitis obliterans and other severe respiratory di

22 mia, more frequent disease, earlier onset of bronchiolitis obliterans and shorter survival.

23 follow-up might be helpful to better manage bronchiolitis obliterans and to detect and treat it earl

24 omplications, however, including infections, bronchiolitis obliterans, and complications of immunosup

25 in treating patients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung trans

26 Idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans are now recognized as part of a

27 ive proportion of patients with fibrosis and bronchiolitis obliterans, at each successive scheduled s

28 brosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectiv

29 Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, w

30 Bronchiolitis obliterans (BO) is a detrimental late pulm

31 Bronchiolitis obliterans (BO) is the pathologic manifest

32 g-term outcome of lung transplantation, with bronchiolitis obliterans (BO) representing the predomina

33 The pathogenesis of bronchiolitis obliterans (BO), a common and devastating

34 ed patient and graft survival, occurrence of bronchiolitis obliterans (BO), and episodes of rejection

35 tion and airway obliteration, which leads to bronchiolitis obliterans (BO), which is pathognomonic fo

36 ontribute to lymphocytic bronchitis (LB) and bronchiolitis obliterans (BO).

37 esize that CMV viremia increases the risk of bronchiolitis obliterans (BOS) or death and retransplant

38 thelial and intraluminal fibrotic lesions of bronchiolitis obliterans by day 28.

39 indicate that they probably had occupational bronchiolitis obliterans caused by the inhalation of vol

40 llular rejection and with the development of bronchiolitis obliterans could not be confirmed in human

41 Bronchiolitis obliterans developed in 29% of patients wi

42 arget tissue that results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD.

43 osttransplantation course was complicated by bronchiolitis obliterans from chronic rejection and by r

44 gressive disease; in contrast, patients with bronchiolitis obliterans from Stevens-Johnson syndrome o

45 Patients with postinfectious bronchiolitis obliterans generally have chronic, nonprog

46 t recipients with histopathologically proved bronchiolitis obliterans (group A) and 21 with normal bi

47 Experimental models of IPS and bronchiolitis obliterans have proven useful to test stra

48 s were identified to show histopathology for bronchiolitis obliterans in all allogeneic grafts.

49 The diagnosis of bronchiolitis obliterans in children can be made with co

50 tation, diagnosis, treatment, and outcome of bronchiolitis obliterans in the nontransplant, pediatric

51 f the lower incidence of acute rejection and bronchiolitis obliterans in younger versus older childre

52 In a different cGVHD model, in which bronchiolitis obliterans is a prominent manifestation, F

53 Bronchiolitis obliterans is a rare form of chronic obstr

54 raft-versus-host disease (GVHD) and IPS, and bronchiolitis obliterans is pathognomonic of chronic GVH

55 Bronchiolitis obliterans is the leading cause of chronic

56 = 89), pulmonary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar pr

57 istress syndrome (n=4), hemosiderosis (n=1), bronchiolitis obliterans (n=1), sarcoidosis (n=1), and b

58 n included pulmonary vascular disease (n=6), bronchiolitis obliterans (n=2), bronchopulmonary dysplas

59 , idiopathic pneumonia syndrome (IPS, n=19), bronchiolitis obliterans (n=22), and other uncommon synd

60 Bronchiolitis obliterans organizing pneumonia (BOOP) and

61 The peak prevalence of bronchiolitis obliterans organizing pneumonia (BOOP) and

62 Bronchiolitis obliterans organizing pneumonia (BOOP) has

63 ganizing diffuse alveolar damage (DAD) in 2, bronchiolitis obliterans organizing pneumonia (BOOP) in

64 Bronchiolitis obliterans organizing pneumonia (BOOP) is

65 Bronchiolitis obliterans organizing pneumonia (BOOP) is

66 interstitial pneumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), an

67 stic plugs within air spaces consistent with bronchiolitis obliterans organizing pneumonia (BOOP).

68 bronchiolitis obliterans syndrome (BOS), and bronchiolitis obliterans organizing pneumonia (BOOP).

69 acute respiratory distress syndrome (n = 2), bronchiolitis obliterans organizing pneumonia (n = 2), p

70 ungal dermatitis, oral herpetic lesions, and bronchiolitis obliterans organizing pneumonia after 2 ep

71 We report the case of a lady who developed bronchiolitis obliterans organizing pneumonia and erythe

72 Bronchiolitis obliterans organizing pneumonia and erythe

73 cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia), and pulm

74 interstitial pneumonia, and the seventh had bronchiolitis obliterans organizing pneumonia.

75 The pathomechanism of bronchiolitis obliterans remains unclear and it remains

76 antly elevated within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.

77 Thin-section CT studies in six patients with bronchiolitis obliterans syndrome (age range, 2 months t

78 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic

79 emic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic

80 genetic polymorphisms on the development of bronchiolitis obliterans syndrome (BOS) after lung trans

81 Bronchiolitis obliterans syndrome (BOS) after lung trans

82 Using log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft surviv

83 the internationally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follo

84 for chronic graft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttr

85 Freedom from bronchiolitis obliterans syndrome (BOS) at three years w

86 Development of bronchiolitis obliterans syndrome (BOS) following lung t

87 d for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine mode

88 plant operation on survival and the onset of bronchiolitis obliterans syndrome (BOS) in consecutive l

89 rentiation is associated with development of bronchiolitis obliterans syndrome (BOS) in human lung al

90 after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

91 lowing lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

92 The term bronchiolitis obliterans syndrome (BOS) is a clinical su

93 Bronchiolitis obliterans syndrome (BOS) is a condition o

94 Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in u

95 Chronic allograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading c

96 Bronchiolitis obliterans syndrome (BOS) is the major lim

97 Bronchiolitis obliterans syndrome (BOS) is the major lim

98 Bronchiolitis obliterans syndrome (BOS) is the major obs

99 Bronchiolitis obliterans syndrome (BOS) is the most comm

100 Bronchiolitis obliterans syndrome (BOS) is the primary l

101 allograft dysfunction (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive a

102 n (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major lim

103 Bronchiolitis obliterans syndrome (BOS) remains the lead

104 Bronchiolitis obliterans syndrome (BOS) remains the main

105 -obliteration of the allograft airway during bronchiolitis obliterans syndrome (BOS) that occurs afte

106 Bronchiolitis obliterans syndrome (BOS), a condition of

107 ement of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition pre

108 s limited by infectious complications and by bronchiolitis obliterans syndrome (BOS), a form of chron

109 Bronchiolitis obliterans syndrome (BOS), a process of fi

110 gnized, idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolit

111 ssion to chronic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarke

112 tive (ELR(+)) CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect

113 n after lung transplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the

114 g to progressive airflow obstruction, termed bronchiolitis obliterans syndrome (BOS), is the major ca

115 man lung allograft rejection, represented by bronchiolitis obliterans syndrome (BOS), is the single m

116 ween these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and g

117 Bronchiolitis obliterans syndrome (BOS), pathognomonic f

118 Bronchiolitis obliterans syndrome (BOS), the clinical co

119 Bronchiolitis obliterans syndrome (BOS), the major cause

120 n the fibro-obliterative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized

121 mputed tomography morphology, mortality, and bronchiolitis obliterans syndrome (BOS)-free survival we

122 al outcomes, often due to the development of bronchiolitis obliterans syndrome (BOS).

123 tation remains limited by the development of bronchiolitis obliterans syndrome (BOS).

124 ejection or infection) (NORMAL POST) or with bronchiolitis obliterans syndrome (BOS).

125 The primary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

126 mortality after lung transplantation (LT) is bronchiolitis obliterans syndrome (BOS).

127 to play an important role in the etiology of bronchiolitis obliterans syndrome (BOS).

128 hether it correlated with the development of bronchiolitis obliterans syndrome (BOS).

129 irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS).

130 splantation may contribute to development of bronchiolitis obliterans syndrome (BOS).

131 al owing to chronic allograft failure termed bronchiolitis obliterans syndrome (BOS).

132 e development of chronic rejection, known as bronchiolitis obliterans syndrome (BOS).

133 all airway injury would increase the risk of bronchiolitis obliterans syndrome (BOS).

134 tation and is an established risk factor for bronchiolitis obliterans syndrome (BOS).

135 The per-protocol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Eve

136 Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of ac

137 o be important in obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS), which severe

138 rvival (P = 0.09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observe

139 sease (P=0.54) nor a subsequent diagnosis of bronchiolitis obliterans syndrome (P=0.70).

140 ce of all other causes (currently defined as bronchiolitis obliterans syndrome [BOS]) is considered t

141 ar that patients may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictiv

142 A diagnosis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) was made in 191

143 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS

144 Infants and young children with bronchiolitis obliterans syndrome after lung transplanta

145 smatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismat

146 study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after L

147 onic lung allograft rejection in the form of bronchiolitis obliterans syndrome and its histopathologi

148 Because current literature suggests bronchiolitis obliterans syndrome and restrictive allogr

149 valuates the current diagnostic criteria for bronchiolitis obliterans syndrome and reviews the epidem

150 rom lung transplant recipients who developed bronchiolitis obliterans syndrome and were compared to s

151 Emphysema, female gender, and bronchiolitis obliterans syndrome are risk factors for s

152 odel demonstrated that the increased risk of bronchiolitis obliterans syndrome associated with primar

153 condary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.

154 sinophilic BAL predisposed to development of bronchiolitis obliterans syndrome but particularly to re

155 d a shorter survival and an earlier onset of bronchiolitis obliterans syndrome compared with patients

156 pha as a potential new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomi

157 This resembles bronchiolitis obliterans syndrome developed following hu

158 Adjustment for clinical variables including bronchiolitis obliterans syndrome did not change this re

159 aft-vs-host disease affects the lung tissue, bronchiolitis obliterans syndrome ensues.

160 A trend, however, toward reduced onset of bronchiolitis obliterans syndrome grade 2 or 3 was obser

161 survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV

162 Patients with bronchiolitis obliterans syndrome had a higher risk of s

163 Bronchiolitis obliterans syndrome has been associated wi

164 o activate fibroblasts in the development of bronchiolitis obliterans syndrome has not been evaluated

165 enance macrolide therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant rec

166 after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant rec

167 ges to the progress of medical management of bronchiolitis obliterans syndrome include difficulties a

168 tion is associated with an increased risk of bronchiolitis obliterans syndrome independent of acute r

169 Bronchiolitis obliterans syndrome is a fibrotic occlusio

170 Bronchiolitis obliterans syndrome is a major problem for

171 Bronchiolitis obliterans syndrome is caused by a fibropr

172 Bronchiolitis obliterans syndrome is characterized by fi

173 Bronchiolitis obliterans syndrome is the leading cause o

174 and were divided into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), earl

175 Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of

176 onic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently descri

177 was not a risk factor for the development of bronchiolitis obliterans syndrome or worse overall survi

178 Bronchiolitis obliterans syndrome remains the leading ca

179 trated that respiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-

180 The remaining four patients had bronchiolitis obliterans syndrome scores of 0 compared w

181 iated with a significantly increased risk of bronchiolitis obliterans syndrome stage 1 (grade 1: rela

182 acute rejection, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage 1, using univari

183 Freedom from bronchiolitis obliterans syndrome was lower, and mortali

184 the association of bronchial dilatation with bronchiolitis obliterans syndrome was significant (P = .

185 s in the six patients with clinically proved bronchiolitis obliterans syndrome were mosaic perfusion

186 Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstac

187 genesis of chronic lung allograft rejection (bronchiolitis obliterans syndrome) remains to be elucida

188 Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the a

189 epatitis C viral RNA (HCV RNA), freedom from bronchiolitis obliterans syndrome, acute rejection, and

190 reported risk factor for the development of bronchiolitis obliterans syndrome, an important cause of

191 e hypertension, renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.

192 nd the first 6 months, bacterial infections, bronchiolitis obliterans syndrome, and survival.

193 tervention in five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatme

194 transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS).

195 s that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled tria

196 Acute rejection is a major risk factor for bronchiolitis obliterans syndrome, but noninvasive bioma

197 ) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limit

198 sponse to viruses and in the pathogenesis of bronchiolitis obliterans syndrome, the predominant manif

199 hown to be implicated in the pathogenesis of bronchiolitis obliterans syndrome, which is considered t

200 Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clin

201 nd 30-day mortality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

202 lantation imitate the in vivo development of bronchiolitis obliterans syndrome-like lesions and revea

203 defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

204 th chronic lung allograft rejection known as bronchiolitis obliterans syndrome.

205 he surviving study subjects remain free from bronchiolitis obliterans syndrome.

206 d the impact of primary graft dysfunction on bronchiolitis obliterans syndrome.

207 gnificant risk factor for the development of bronchiolitis obliterans syndrome.

208 rences were observed in the overall onset of bronchiolitis obliterans syndrome.

209 recipients is limited by the development of bronchiolitis obliterans syndrome.

210 y may improve lung function in patients with bronchiolitis obliterans syndrome.

211 the main risk factor for the development of bronchiolitis obliterans syndrome.

212 ection has been linked to the development of bronchiolitis obliterans syndrome.

213 fts due to acute rejection (AR) or developed bronchiolitis obliterans syndrome.

214 ociated with an increased risk of developing bronchiolitis obliterans syndrome.

215 reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

216 n of epithelial to mesenchymal transition in bronchiolitis obliterans syndrome.

217 ortality after lung transplantation (LTX) is bronchiolitis obliterans syndrome.

218 ng transplant patients prior to diagnosis of bronchiolitis obliterans syndrome.

219 ted rejection, acute cellular rejection, and bronchiolitis obliterans syndrome; however, the signific

220 ces epithelial injury via TGF-beta in murine bronchiolitis obliterans; that TGF-beta and the C' casca

221 occur and increase the chance of developing bronchiolitis obliterans; therefore, many centers perfor

222 11 years), the overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overal

223 Major risk factors for the development of bronchiolitis obliterans were age older than 3 years, mo

224 nced bronchus-associated lymphoid tissue and bronchiolitis obliterans were unique for the immunizing

225 rgan system, nonsclerodermatous disease with bronchiolitis obliterans where cGVHD is dependent on ant

226 The major late complication was bronchiolitis obliterans, which occurred in 27% of patie

227 Bronchiolitis obliterans with organizing pneumonia (BOOP

228 c encepatholopathy and pulmonary findings of bronchiolitis obliterans with organizing pneumonia (BOOP